Semaglutide vs Adrenomedullin
Side-by-Side Comparison
| Attribute | Semaglutide | Adrenomedullin |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Cardiovascular / Vasoactive |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. | Adrenomedullin signals through the calcitonin receptor-like receptor (CLR) complexed with receptor activity-modifying protein 2 or 3 (RAMP2/RAMP3), forming the AM1 and AM2 receptors respectively. |
| Evidence Rating | A — FDA Approved | D — Biomarker / Early Research |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | Research stage. MR-proADM used as prognostic biomarker in sepsis and heart failure. No approved therapeutic use of adrenomedullin peptide. |
| Safety Profile | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness | No human safety data from controlled therapeutic trials; Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia |
| Route | Subcutaneous (weekly injection); Oral tablet available (Rybelsus) | Intravenous infusion (research only) |
| Dose Range | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day | 10–50 ng/kg/min in human physiological studies |
| Frequency | Once weekly (SC); Once daily (oral) | Continuous or bolus infusion |
| Molecular Weight | ~4113.6 g/mol | ~6028 g/mol |
| Half-Life | ~160–168 hours (~7 days) | ~22 minutes (plasma) |
Overview
Semaglutide and Adrenomedullin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Semaglutide — Mechanism & Evidence
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1. It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). Developed by Novo Nordisk and first FDA-approved December 5, 2017, it is backed by the extensive STEP and SUSTAIN trial programs involving thousands of patients. There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
Adrenomedullin — Mechanism & Evidence
Adrenomedullin is a 52-amino-acid vasodilatory peptide (MW ~6028 g/mol) originally isolated from human pheochromocytoma tissue. It is widely expressed in the cardiovascular system, lungs, kidneys, and adrenal glands, with potent vasodilatory, natriuretic, and cardioprotective properties. It is currently investigated as a biomarker (MR-proADM) for sepsis and heart failure prognosis, with no approved therapeutic use of the peptide itself.
Key claims: MR-proADM is a strong prognostic biomarker in sepsis; MR-proADM predicts mortality in acute heart failure; Adrenomedullin has potent vasodilatory effects in humans.
Shared Research Applications
These peptides target different research areas. Semaglutide focuses on Weight Management, Metabolic Health, Cardiovascular, while Adrenomedullin targets Sepsis Prognostication, Heart Failure Biomarker, Cardiovascular Research.
Safety Considerations
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
Adrenomedullin: No human safety data from controlled therapeutic trials Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia Theoretical risk of excessive vasodilation and hemodynamic instability
Related Products
Related Research News
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.